US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OnKure Therapeutics, Inc.

2.84

+0.310012.25%

Volume:121.66K

Turnover:334.74K

Market Cap:38.43M

PE:-0.47

High:2.85

Open:2.49

Low:2.49

Close:2.53

52wk High:190.00

52wk Low:1.70

Shares:13.53M

Float Shares:3.95M

Volume Ratio:0.47

T/O Rate:3.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.0174

EPS(LYR):-15.2805

ROE:-142.90%

ROA:-70.95%

PB:0.49

PE(LYR):-0.19

Loading ...

Overview Company News Filings

Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

OnKure Therapeutics Q2 2025 Results: Net Loss Widened to $15.4M, EPS at $1.14, R&D Expenses Increased to $12.6M

Onkure Therapeutics Inc - Cash Position of $83.4 Mln Expected to Provide Cash Runway Into Q4 2026

THOMSON REUTERS

Onkure Therapeutics Inc - Net Loss $1.14 per Share in Q2 2025

THOMSON REUTERS

Jason A. Leverone, CFO of Onkure Therapeutics Inc., Reports Disposal of Common Shares

OnKure Therapeutics Inc. Conducted Annual Meeting of Stockholders

Cormorant Asset Management Reports Disposal of Onkure Therapeutics Inc. Common Shares

Acorn Bioventures, L.P. Reports Acquisition of Common Shares of Onkure Therapeutics Inc

Cormorant Asset Management Reports Disposal of Common Shares in Onkure Therapeutics Inc

Oppenheimer Keeps Their Buy Rating on OnKure Therapeutics (OKUR)

Onkure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

Press Release: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Onkure Therapeutics Inc expected to post a loss of $1.46 a share - Earnings Preview

Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating

MT Newswires Live

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate

Simply Wall St.

OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies

OnKure Therapeutics Is Maintained at Outperform by Oppenheimer

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OKUR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OKUR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","market":"US","secType":"STK","nameCN":"OnKure Therapeutics, Inc.","latestPrice":2.84,"timestamp":1755542726684,"preClose":2.53,"halted":0,"volume":121657,"delay":0,"floatShares":3953122,"shares":13529961,"eps":-6.017358,"marketStatus":"Trading","change":0.31,"latestTime":"08-18 14:46:39 EDT","open":2.49,"high":2.85,"low":2.49,"amount":334740.0019391,"amplitude":0.142292,"askPrice":2.86,"askSize":10,"bidPrice":2.82,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-6.017358,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1755547200000},"marketStatusCode":2,"adr":0,"listingDate":1617940800000,"exchange":"NASDAQ","adjPreClose":2.53,"preHourTrading":{"tag":"盘前","latestPrice":2.45,"preClose":2.53,"latestTime":"09:18 EDT","volume":4524,"amount":10619.800464,"timestamp":1755523127400},"postHourTrading":{"tag":"盘后","latestPrice":2.4399,"preClose":2.53,"latestTime":"19:59 EDT","volume":1908,"amount":4696.93,"timestamp":1755302350486},"volumeRatio":0.472994},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","floatShares":3953122,"roa":"-70.95%","roe":"-142.90%","lyrEps":-15.280509,"volumeRatio":0.472994,"shares":13529961,"dividePrice":0,"high":2.85,"amplitude":0.142292,"preClose":2.53,"low":2.49,"week52Low":1.7,"pbRate":"0.49","week52High":190,"institutionHeld":0,"latestPrice":2.84,"committee":0.285714,"eps":-6.017358,"divideRate":0,"volume":121657,"delay":0,"ttmEps":-6.017358,"open":2.49,"prevYearClose":8.6,"prevWeekClose":2.53,"prevMonthClose":2.21,"prevQuarterClose":2.39,"fiveDayClose":2.03,"twentyDayClose":2.32,"sixtyDayClose":2.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OKUR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"OKUR","fiscalQuarterEnding":"2025/06","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-1.14},{"market":"US","date":"2025-05-06","symbol":"OKUR","fiscalQuarterEnding":"2025/03","expectedEps":-1.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2025-03-10","symbol":"OKUR","fiscalQuarterEnding":"2024/12","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OKUR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OKUR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1746072000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OKUR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OKUR","date":"2025-08-15","current":-0.598959,"percent":0.677885,"low":-5.826698,"twenty":-2.539746,"median":-1.170006,"eighty":-0.552659,"high":-0.416488,"avg":-1.715075,"sd":1.54938,"marketCap":36124995},"quantilePoints":[{"date":"2024-10-18","current":-0.566743,"twenty":-0.590487,"median":-0.58695,"eighty":-0.578615,"marketCap":23873500},{"date":"2024-10-25","current":-5.440362,"twenty":-1.566804,"median":-0.588529,"eighty":-0.583857,"marketCap":229169826},{"date":"2024-10-31","current":-5.53853,"twenty":-5.51383,"median":-0.595209,"eighty":-0.585182,"marketCap":233305021},{"date":"2024-11-08","current":-5.443529,"twenty":-5.51383,"median":-5.168028,"eighty":-0.586445,"marketCap":229303220},{"date":"2024-11-15","current":-5.044864,"twenty":-5.465063,"median":-5.164656,"eighty":-0.588845,"marketCap":225434812},{"date":"2024-11-22","current":-4.773218,"twenty":-5.441629,"median":-5.044864,"eighty":-0.591244,"marketCap":213296014},{"date":"2024-11-29","current":-4.603066,"twenty":-5.421362,"median":-4.955311,"eighty":-0.594567,"marketCap":205692591},{"date":"2024-12-06","current":-4.23888,"twenty":-5.387795,"median":-4.77471,"eighty":-2.052213,"marketCap":189418599},{"date":"2024-12-13","current":-3.232892,"twenty":-5.327258,"median":-4.623962,"eighty":-3.414388,"marketCap":144465030},{"date":"2024-12-20","current":-2.403027,"twenty":-5.244271,"median":-4.603066,"eighty":-2.584523,"marketCap":107381670},{"date":"2024-12-27","current":-2.444819,"twenty":-5.224724,"median":-4.480676,"eighty":-2.411385,"marketCap":109249178},{"date":"2025-01-03","current":-2.543328,"twenty":-5.168028,"median":-4.415003,"eighty":-2.435864,"marketCap":113651159},{"date":"2025-01-10","current":-2.331384,"twenty":-5.162633,"median":-4.235895,"eighty":-2.394669,"marketCap":104180229},{"date":"2025-01-17","current":-1.794061,"twenty":-5.159079,"median":-4.098579,"eighty":-2.308697,"marketCap":80169421},{"date":"2025-01-24","current":-1.605998,"twenty":-5.09033,"median":-3.232892,"eighty":-1.908093,"marketCap":71765638},{"date":"2025-01-31","current":-1.740329,"twenty":-5.041282,"median":-2.694077,"eighty":-1.735553,"marketCap":77768340},{"date":"2025-02-07","current":-1.698537,"twenty":-4.988744,"median":-2.570194,"eighty":-1.722418,"marketCap":75900833},{"date":"2025-02-14","current":-1.680626,"twenty":-4.917698,"median":-2.540343,"eighty":-1.700328,"marketCap":75100472},{"date":"2025-02-21","current":-1.629879,"twenty":-4.846055,"median":-2.485118,"eighty":-1.698537,"marketCap":72832785},{"date":"2025-02-28","current":-1.459727,"twenty":-4.775009,"median":-2.435864,"eighty":-1.629879,"marketCap":65229362},{"date":"2025-03-07","current":-1.510474,"twenty":-4.72068,"median":-2.35825,"eighty":-1.588087,"marketCap":67497050},{"date":"2025-03-14","current":-1.170006,"twenty":-4.634708,"median":-2.331384,"eighty":-1.520623,"marketCap":61627741},{"date":"2025-03-21","current":-1.2754,"twenty":-4.622768,"median":-2.038842,"eighty":-1.494951,"marketCap":67179130},{"date":"2025-03-28","current":-1.196325,"twenty":-4.613812,"median":-1.835853,"eighty":-1.463309,"marketCap":63014023},{"date":"2025-04-04","current":-0.992261,"twenty":-4.603066,"median":-1.777643,"eighty":-1.2754,"marketCap":52265363},{"date":"2025-04-11","current":-0.755037,"twenty":-4.555304,"median":-1.746299,"eighty":-1.238668,"marketCap":39770044},{"date":"2025-04-17","current":-0.747384,"twenty":-4.482467,"median":-1.737344,"eighty":-1.209875,"marketCap":39366970},{"date":"2025-04-25","current":-0.675962,"twenty":-4.474705,"median":-1.713463,"eighty":-1.144127,"marketCap":35604938},{"date":"2025-05-02","current":-0.6377,"twenty":-4.44366,"median":-1.701522,"eighty":-1.004505,"marketCap":33589565},{"date":"2025-05-09","current":-0.454974,"twenty":-4.341569,"median":-1.694059,"eighty":-0.784115,"marketCap":26871652},{"date":"2025-05-16","current":-0.468834,"twenty":-4.237686,"median":-1.629879,"eighty":-0.752996,"marketCap":27690262},{"date":"2025-05-23","current":-0.489317,"twenty":-4.231716,"median":-1.626894,"eighty":-0.697899,"marketCap":28900031},{"date":"2025-05-30","current":-0.583311,"twenty":-4.22694,"median":-1.591073,"eighty":-0.663208,"marketCap":34451517},{"date":"2025-06-06","current":-0.654223,"twenty":-4.098579,"median":-1.549281,"eighty":-0.645352,"marketCap":38639741},{"date":"2025-06-13","current":-0.651936,"twenty":-3.686632,"median":-1.511967,"eighty":-0.647361,"marketCap":38504637},{"date":"2025-06-20","current":-0.553574,"twenty":-3.32364,"median":-1.503011,"eighty":-0.6377,"marketCap":32695165},{"date":"2025-06-27","current":-0.576449,"twenty":-3.001246,"median":-1.480623,"eighty":-0.606186,"marketCap":34046205},{"date":"2025-07-03","current":-0.544424,"twenty":-2.803631,"median":-1.468682,"eighty":-0.59365,"marketCap":32154749},{"date":"2025-07-11","current":-0.583311,"twenty":-2.690793,"median":-1.364985,"eighty":-0.585652,"marketCap":34451517},{"date":"2025-07-18","current":-0.544424,"twenty":-2.634673,"median":-1.2754,"eighty":-0.583311,"marketCap":32154749},{"date":"2025-07-25","current":-0.542136,"twenty":-2.584523,"median":-1.253011,"eighty":-0.577821,"marketCap":32019645},{"date":"2025-08-01","current":-0.505536,"twenty":-2.568403,"median":-1.219282,"eighty":-0.570959,"marketCap":29857981},{"date":"2025-08-08","current":-0.459786,"twenty":-2.55288,"median":-1.202702,"eighty":-0.560894,"marketCap":27155901},{"date":"2025-08-15","current":-0.598959,"twenty":-2.539746,"median":-1.170006,"eighty":-0.552659,"marketCap":36124995}],"updateTime":1755542799490},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OKUR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559624807","title":"Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559624807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559624807?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:40","pubTimestamp":1755031207,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryOnkure Therapeutics Inc OKUR.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended June","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U41VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2559621198","title":"OnKure Therapeutics Q2 2025 Results: Net Loss Widened to $15.4M, EPS at $1.14, R&D Expenses Increased to $12.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621198","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621198?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:21","pubTimestamp":1755030074,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics, Inc. , a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $15.4 million, compared to a net loss of $14.1 million in the same quarter of 2024. Research and development expenses rose to $12.6 million from $10.8 million in the previous year, driven by increased clinical trial, outsourced manufacturing, and research expenses. General and administrative expenses saw a slight increase to $3.7 million from $3.6 million, attributed to higher personnel-related costs and professional service fees, partially offset by a reduction in legal expenses. The company's cash and cash equivalents stood at $83.4 million as of June 30, 2025, expected to support operations into the fourth quarter of 2026. OnKure is advancing its lead asset, OKI-219, with the PIKture-01 phase 1 clinical trial on track for data release in the fourth quarter of 2025. The trial includes new expansion arms ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLbV99SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2559621728","title":"Onkure Therapeutics Inc - Cash Position of $83.4 Mln Expected to Provide Cash Runway Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621728?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5KS7KS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","OKUR"],"gpt_icon":0},{"id":"2559621726","title":"Onkure Therapeutics Inc - Net Loss $1.14 per Share in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621726?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5KS7KS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","OKUR","BK4139"],"gpt_icon":0},{"id":"2546221245","title":"Jason A. Leverone, CFO of Onkure Therapeutics Inc., Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2546221245","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546221245?lang=en_us&edition=fundamental","pubTime":"2025-06-26 06:50","pubTimestamp":1750891821,"startTime":"0","endTime":"0","summary":"Jason A. Leverone, Chief Financial Officer of Onkure Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6DftGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Jason A. Leverone, CFO of Onkure Therapeutics Inc., Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","BK4539","BK4139"],"gpt_icon":0},{"id":"2539440928","title":"OnKure Therapeutics Inc. Conducted Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2539440928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539440928?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:30","pubTimestamp":1748464253,"startTime":"0","endTime":"0","summary":"On May 27, 2025, OnKure Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. During the meeting, stockholders elected Drs. Isaac Manke and Nicholas Saccomano as Class I directors of the Board. Additionally, the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Both proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL6bGY37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR","BK4539"],"gpt_icon":0},{"id":"2536265810","title":"Cormorant Asset Management Reports Disposal of Onkure Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2536265810","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536265810?lang=en_us&edition=fundamental","pubTime":"2025-05-20 05:33","pubTimestamp":1747690428,"startTime":"0","endTime":"0","summary":"Cormorant Asset Management, LP has reported a disposal of common shares of Onkure Therapeutics Inc. The form was filed by more than one reporting person, including Cormorant Asset Management, LP and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLWZMMb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","BK4139","BK4539"],"gpt_icon":0},{"id":"2536630998","title":"Acorn Bioventures, L.P. Reports Acquisition of Common Shares of Onkure Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536630998","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536630998?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:44","pubTimestamp":1747687449,"startTime":"0","endTime":"0","summary":"Acorn Bioventures, L.P. reported an acquisition of common shares of Onkure Therapeutics Inc. The form was filed by more than one reporting person, including Acorn Capital Advisors GP, LLC and Anders Hove, Manager, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL9TpKx1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR","BK4539"],"gpt_icon":0},{"id":"2535001080","title":"Cormorant Asset Management Reports Disposal of Common Shares in Onkure Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2535001080","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535001080?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:36","pubTimestamp":1747255006,"startTime":"0","endTime":"0","summary":"Cormorant Asset Management, LP reported a disposal of Class A Common Stock of OnKure Therapeutics, Inc. The form was filed by more than one reporting person, including Cormorant Asset Management, LP among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL8N6C3G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR","BK4539"],"gpt_icon":0},{"id":"2533667139","title":"Oppenheimer Keeps Their Buy Rating on OnKure Therapeutics (OKUR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533667139","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533667139?lang=en_us&edition=fundamental","pubTime":"2025-05-07 04:35","pubTimestamp":1746563758,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on OnKure Therapeutics (OKUR – Research Report), with a price ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-onkure-therapeutics-okur?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-keeps-their-buy-rating-on-onkure-therapeutics-okur?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","OKUR"],"gpt_icon":0},{"id":"2533633263","title":"Onkure Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533633263","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533633263?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:43","pubTimestamp":1746535419,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryOnkure Therapeutics Inc OKUR.OQ reported a quarterly adjusted loss of $1.19 per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL8N3RE1DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2533268237","title":"OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533268237","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533268237?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:47","pubTimestamp":1746532049,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(1.46) by 18.49 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45218385/onkure-therapeutics-q1-eps-1-19-beats-1-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","LENZ"],"gpt_icon":0},{"id":"2533684393","title":"Press Release: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2533684393","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533684393?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:30","pubTimestamp":1746531000,"startTime":"0","endTime":"0","summary":"-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data. -- Expansion of the Company's PI3Ka franchise with the planned announcement of a pan-mutant selective development candidate in Q2 2025. -- $96.7M in cash and cash equivalents expected to be sufficient to fund operations through multiple anticipated milestones into Q4 2026. BOULDER, Colo., May 06, 2025  -- OnKure Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today reported financial results for the quarter ended March 31, 2025, and provided business highlights.\"Building on the advancement of our initial candidate, our research and development team is advancing towards a second development candidate in the second quarter of 2025; a true pan-mutant inhibitor with a selectivity profile that augurs well for rendering all major PI3Ka mutants actio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OKUR","BK4139","LENZ"],"gpt_icon":0},{"id":"2532497678","title":"Onkure Therapeutics Inc  expected to post a loss of $1.46 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2532497678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532497678?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:24","pubTimestamp":1746192246,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics Inc  expected to post a loss of $1.46 a share - Earnings Preview Onkure Therapeutics Inc OKUR.OQ OKUR.O is expected to show no change in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL8N3RA1WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2531031031","title":"Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031031?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:11","pubTimestamp":1746015089,"startTime":"0","endTime":"0","summary":"Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","OKUR"],"gpt_icon":0},{"id":"2523664639","title":"We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523664639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523664639?lang=en_us&edition=fundamental","pubTime":"2025-03-29 22:36","pubTimestamp":1743259012,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-okur/onkure-therapeutics/news/were-keeping-an-eye-on-onkure-therapeutics-nasdaqokur-cash-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","IE00B3QW5Z07.USD","QID",".IXIC","PSQ","NVIW.SI","USAW.SI","TQQQ","LU2095319765.USD","IE00BKPKM429.USD","LU2210150020.SGD","SQQQ","NQmain","OKUR","TSYW.SI","USJW.SI","BK4585","BK4112","NDAQ","MNQmain","IE00BGHQF748.EUR","QLD","BK4588"],"gpt_icon":1},{"id":"2520621318","title":"OnKure Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520621318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520621318?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:28","pubTimestamp":1742297280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 07:28 ET (11:28 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","LENZ"],"gpt_icon":0},{"id":"2518037523","title":"Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2518037523","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518037523?lang=en_us&edition=fundamental","pubTime":"2025-03-12 14:00","pubTimestamp":1741759222,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Competition category. Onkure Therapeutics, Inc. faces substantial competition in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-stiff-competition-in-the-pharmaceutical-sector-challenges-in-commercializing-pi3ka-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/onkure-therapeutics-faces-stiff-competition-in-the-pharmaceutical-sector-challenges-in-commercializing-pi3ka-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKUR","BK4139","LENZ"],"gpt_icon":0},{"id":"2518746576","title":"OnKure Therapeutics Is Maintained at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518746576?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:50","pubTimestamp":1741697400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 08:50 ET (12:50 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","OKUR","LENZ"],"gpt_icon":0},{"id":"2518745263","title":"Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2518745263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518745263?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:40","pubTimestamp":1741696819,"startTime":"0","endTime":"0","summary":"Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","LENZ","OKUR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}